SCHEMBL20157547

SCHEMBL20157547

Cc1ccc(C(=O)c2ccc(F)cc2)c(Br)c1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
HTT P42858 2/20 0.50
NPC1 O15118 1/20 0.50
MAPK1 P28482 1/20 0.50
F2 P00734 1/20 0.46
PLAU P00749 1/20 0.46
ELANE P08246 1/20 0.46
LMNA P02545 4/20 0.44
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
KCNMA1 Q12791 1/20 0.44
TP53 P04637 1/20 0.44
KMT2A Q03164 1/20 0.44
RXRA P19793 1/20 0.42
AKR1C3 P42330 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfamide SCHEMBL21352062 0.93 MAPT (0.48) MAPTHTTNPC1MAPK1F2
SCHEMBL20157554 0.87 MAPT (0.54) MAPTHTTNPC1MAPK1F2
SCHEMBL11860220 0.86 LTA4H (0.46) MAPTNPC1MAPK1LMNAALDH1A1
SCHEMBL20157816 0.85 MAPT (0.51) MAPTHTTNPC1MAPK1LMNA
SCHEMBL1584825 0.84 F2 (0.59) MAPTHTTNPC1MAPK1F2
SCHEMBL20157798 0.83 MAPT (0.50) MAPTHTTNPC1MAPK1LMNA
SCHEMBL14099187 0.83 LMNA (0.50) MAPTHTTNPC1MAPK1F2
SCHEMBL7213795 0.83 MAPT (0.53) MAPTHTTNPC1MAPK1SMN1; SMN2
SCHEMBL30882570 0.83 MAPT (0.53) MAPTHTTNPC1MAPK1SMN1; SMN2
SCHEMBL20157894 0.82 CES2 (0.50) HTTLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 EP disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 EP disclosed
WO-2018086605-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 山东罗欣药业集团股份有限公司 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 MAPT 237/4885HTT 1073/4885NPC1 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.